Bashar Kahaleh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9415075/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	Review: Evidence That Systemic Sclerosis Is a Vascular Disease. Arthritis and Rheumatism, 2013, 65, 1953-1962.	6.7	339
3	Association between enhanced type I collagen expression and epigenetic repression of theFLI1 gene in scleroderma fibroblasts. Arthritis and Rheumatism, 2006, 54, 2271-2279.	6.7	319
4	Cardiovascular disease in autoimmune rheumatic diseases. Autoimmunity Reviews, 2013, 12, 1004-1015.	5.8	232
5	The effect of dynamic versus isometric resistance training on pain and functioning among adults with osteoarthritis of the knee. Archives of Physical Medicine and Rehabilitation, 2002, 83, 1187-1195.	0.9	209
6	International consensus criteria for the diagnosis of Raynaud's phenomenon. Journal of Autoimmunity, 2014, 48-49, 60-65.	6.5	170
7	Vascular Disease in Scleroderma: Mechanisms of Vascular Injury. Rheumatic Disease Clinics of North America, 2008, 34, 57-71.	1.9	113
8	Raynaud's phenomenon and scleroderma dysregulated neuroendothelial control of vascular tone. Arthritis and Rheumatism, 1995, 38, 1-4.	6.7	95
9	Endothelial dysfunction in systemic sclerosis. Current Opinion in Rheumatology, 2014, 26, 615-620.	4.3	77
10	Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. Journal of Cellular and Molecular Medicine, 2013, 17, 1291-1299.	3.6	76
11	Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology, 2015, 54, 1759-1770.	1.9	73
12	The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis and Rheumatism, 2005, 52, 3618-3628.	6.7	55
13	Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Frontiers in Immunology, 2018, 9, 2191.	4.8	53
14	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
15	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	5.8	38
16	Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Research and Therapy, 2016, 18, 228.	3.5	30
17	Epigenetics and systemic sclerosis. Seminars in Immunopathology, 2015, 37, 453-462.	6.1	27
18	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheumatology, 2016, 55, 745-754.	1.9	24

BASHAR KAHALEH

#	Article	lF	CITATIONS
19	Progress in research into systemic sclerosis. Lancet, The, 2004, 364, 561-562.	13.7	20
20	Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral―challenge for future research in scleroderma. Autoimmunity Reviews, 2021, 20, 102899.	5.8	15
21	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
22	Mechanism and biomarkers in aortitis––a review. Journal of Molecular Medicine, 2020, 98, 11-23.	3.9	13
23	Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, 2020, 7, 147-156.	0.6	11
24	ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. Rheumatology, 2021, 60, 5509-5516.	1.9	10
25	Epigenetic downâ€regulation of microRNAâ€126 in scleroderma endothelial cells is associated with impaired responses to VECF and defective angiogenesis. Journal of Cellular and Molecular Medicine, 2021, 25, 7078-7088.	3.6	10
26	Evaluation of topical econazole nitrate formulations with potential for treating Raynaud's phenomenon. Pharmaceutical Development and Technology, 2019, 24, 689-699.	2.4	8
27	Ultrasound-mediated topical delivery of econazole nitrate with potential for treating Raynaud's phenomenon. International Journal of Pharmaceutics, 2020, 580, 119229.	5.2	6
28	An elderly man with vasculitis and IgA myeloma. Journal of the European Academy of Dermatology and Venereology, 1998, 10, 186-187.	2.4	4
29	Genome-wide DNA methylation pattern in systemic sclerosis microvascular endothelial cells: Identification of epigenetically affected key genes and pathways. Journal of Scleroderma and Related Disorders, 2022, 7, 71-81.	1.7	4
30	Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, 2020, 7, S147-S156.	0.6	4
31	Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation. Journal of Scleroderma and Related Disorders, 2016, 1, 7-9.	1.7	3
32	Recent updates in experimental protocols for endothelial cells. Journal of Scleroderma and Related Disorders, 2016, 1, 257-265.	1.7	3
33	Mechanisms of Vascular Disease. , 2017, , 221-244.		1
34	Potential beneficial role for endothelin in scleroderma vasculopathy: inhibition of endothelial apoptosis by type B endothelin-receptor signaling. Journal of Scleroderma and Related Disorders, 2016, 1, 213-219.	1.7	0
35	Epigenetics of Systemic Sclerosis. , 2019, , 505-528.		0

0

#	Article	IF	CITATIONS
37	Recurrent Episodes of Myocardial Infarction in a 25-Year-Old Young Man With Systemic Lupus Erythematosus. Archives of Rheumatology, 2018, 33, 102-104.	0.9	0